|
US2008275049A1
|
|
Methods and Compositions for Upregulation of GATA Activity
|
|
WO2008091338A1
|
|
Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
|
|
WO2008036966A2
|
|
Methods and compositions for the treatment of inflammation, obesity and related metabolic disorders
|
|
WO2008036967A2
|
|
Novel heterocyclic compounds as lasy activators
|
|
CA2654608A1
|
|
Compositions and methods to enhance reverse cholesterol transport
|
|
NZ569415A
|
|
Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
|
|
WO2006069162A1
|
|
Novel heterocyclic compounds and their pharmaceutical compositions
|
|
CN101107250A
|
|
Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
|
|
WO2005103015A1
|
|
Triazine compounds and their analogs, compositions, and methods
|
|
EP1678157A2
|
|
Heterocyclic compounds and methods of making and using thereof
|
|
BRPI0414737A
|
|
heterocyclic compounds and methods of preparing and using these
|
|
US7163943B2
|
|
Methods and compositions of novel triazine compounds
|
|
US7112587B2
|
|
Methods and compositions of novel triazine compounds
|
|
US7169785B2
|
|
Methods and compositions of novel triazine compounds
|
|
CN1697831A
|
|
Methods and compositions of novel triazine compounds
|
|
US7132423B2
|
|
Methods and compositions of novel triazine compounds
|
|
US7173032B2
|
|
Methods and compositions of novel triazine compounds
|
|
WO03065008A2
|
|
Methods and compositions for identification and therapeutic use of genes involved in vascular and proliferative diseases
|
|
NZ532349A
|
|
Methods and compositions of novel triazine compounds
|
|
AU2002322862A1
|
|
Methods and compositions for diagnosis and treatment of vascular conditions
|
